Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
nanvuranlat (JPH203)
i
Other names:
JPH203, JPH 203, KYT-0353, KYT0353, KYT 0353, JPH203-SBECD
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
J-Pharma, Ohara Pharma
Drug class:
SLC7A5 inhibitor
‹
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
SLC7A5 overexpression
Biliary Tract Cancer
SLC7A5 overexpression
Biliary Tract Cancer
JPH203
Sensitive: C3 – Early Trials
JPH203
Sensitive
:
C3
JPH203
Sensitive: C3 – Early Trials
JPH203
Sensitive
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.